title: The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus.
abstract: A randomized, double-blind, placebo-controlled trial was conducted, to determine whether the co-administration of ivermectin with albendazole is safe and more effective against Onchocerca volvulus than ivermectin alone, and whether a significant pharmacokinetic interaction occurs. Forty-two male onchocerciasis patients received ivermectin (200 mug/kg) alone, albendazole (400 mg) alone or the combination. Safety was determined from the results of detailed clinical and laboratory examinations before treatment, during hospitalization and on day 30. Microfilaricidal efficacy was estimated from the reductions in skin counts between day 0 (pretreatment) and day 30. To determine efficacy against the adult worms, two independent observers examined histology slides prepared from nodules excised on day 180; changes in the skin counts of skin microfilariae between days 30 and 365 provided additional indicators of the level of adulticidal activity. Pharmacokinetic parameters for ivermectin and albendazole sulphoxide were defined over 72 h post-treatment. The co-administration of ivermectin with albendazole did not produce more severe adverse effects than ivermectin alone. Both nodule examiners found that the combination was not macrofilaricidal and that it was not clearly superior to ivermectin alone in the effects on reproductive activity; this was supported by the similar efficacy of the two regimens in the suppression of skin microfilariae. There was no significant pharmacokinetic interaction. Although the co-administration of ivermectin with albendazole appears safe, it offers no advantage over ivermectin alone in the control of onchocerciasis. The combination does not require an alteration in the dosage of either component.
authors.affiliation: Onchocerciasis Chemotherapy Research Centre, Hohoe Hospital, P.O. Box 144, Hohoe, Ghana.
authors.forename: K
authors.initials: K
authors.lastname: Awadzi
authors.forename: G
authors.initials: G
authors.lastname: Edwards
authors.forename: B O L
authors.initials: BO
authors.lastname: Duke
authors.forename: N O
authors.initials: NO
authors.lastname: Opoku
authors.forename: S K
authors.initials: SK
authors.lastname: Attah
authors.forename: E T
authors.initials: ET
authors.lastname: Addy
authors.forename: A E
authors.initials: AE
authors.lastname: Ardrey
authors.forename: B T
authors.initials: BT
authors.lastname: Quartey
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015766:Albendazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005369:Filaricides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D008842:Microfilariae / Q000187:drug effects; D008875:Middle Aged; D017181:Onchocerca volvulus / Q000187:drug effects*; D009855:Onchocerciasis / Q000188:drug therapy*
chemical_list: D000871:Anthelmintics; D005369:Filaricides; D007559:Ivermectin; D015766:Albendazole; C027186:albendazole sulfoxide